Prompt hemostasis and effective incision closure have been paramount concerns for surgeons for decades. As medical technology advances, the surgeon’s toolbox expands to include more effective products such as biosurgery hemostats that actively cease bleeding.
Hemostats are agents used to promote and accelerate hemostasis to control bleeding in cases where application of pressure, ligature, and other conventional methods are ineffective. They are inserted to remove excess blood, prevent further bleeding, and clear up the operating site for the surgeon. Hemostats include active (thrombin-based), combination, and passive hemostats (oxidised regenerated cellulose-based, gelatin-based, and collagen-based).
Although high costs, weak reimbursement, and stringent regulatory guidelines in some markets prevent wider adoption of products, the biosurgery hemostats market is expected to steadily flourish to address an expanding array of clinical applications and surgical specialties, according to GlobalData.
The global hemostats market, valued at $2.4bn in 2017, is expanding at a compound annual growth rate (CAGR) of 5.0% to reach $3.4bn in 2024.